Indianapolis publication says termination of PFE-Biocon insulin-FoB collaboration (#msg-73189352) is highly bullish for LLY: http://www.ibj.com/lilly-gets-good-news-on-insulin/PARAMS/article/33325 This premise is somewhat tenuous, IMHO.